Santen Pharmaceutical Co (SNPHY) AI Stock Analysis

Santen Pharmaceutical Co

(Other OTC:SNPHY)

Select Model

Rating:58Neutral

Price Target:$11.50▲(2.37% Upside)

Action:reiterated

Date:08/10/26

SNPHY scores a 58, reflecting a company in recovery with meaningful strengths but also notable concerns. The strongest factor is the fortress-like balance sheet with minimal leverage, providing resilience and flexibility. The profitability turnaround from FY2023's net loss is encouraging, with margins steadily improving. However, the declining cash flow conversion despite rising earnings is a key risk that weighs on the score, as does modest and uneven revenue growth. Technically, the stock shows short-term weakness trading below near-term moving averages with negative MACD, though longer-term trends remain supportive. Valuation is fair at 16x earnings but does not offer a compelling margin of safety. Overall, SNPHY is a stable but unexciting holding — suitable for conservative investors seeking pharmaceutical exposure with low leverage, but lacking the growth catalysts or cash flow momentum to warrant a higher score.

Positive Factors

Strong Profitability RecoveryThe return to consistent profitability after the FY2023 loss indicates a materially stronger earnings base. Healthy gross, operating, and net margins provide capacity to fund research, product launches, market expansion, and shareholder returns over the next several quarters.

Negative Factors

Uneven Operating Cash ConversionWeak and variable conversion of earnings into operating cash can limit the predictability of internally funded growth. Although free cash flow remains positive, recurring volatility may complicate investment planning and reduce confidence that accounting profits translate consistently into liquidity.

Santen Pharmaceutical Co (SNPHY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $3.64B
Dividend Yield: 2.00%
Average Volume (3M): 2,131
Price to Earnings (P/E): 15.0
Beta (1Y): -0.01
Revenue Growth: -3.73%
EPS Growth: 26.50%
Country: US
Employees: 3,968
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a s...

How the Company Makes Money

Santen primarily makes money by selling ophthalmic pharmaceutical products. Revenue is generated through (1) sales of prescription eye-drop and other ophthalmic medicines to wholesalers, hospitals, clinics, and pharmacies in its core markets (histori...

Santen Pharmaceutical Co Financial Statement Overview

Summary

Santen has executed a solid turnaround from its FY2023 net loss, with net income recovering to ~¥36-39 billion and net margins reaching 12-13%. The balance sheet is a clear strength with a debt-to-equity ratio of just 0.10-0.12, providing significant financial flexibility. However, declining operating cash flow (from ¥72.6B to ~¥42.2B TTM) despite rising profits is a notable concern, as cash conversion ratios have deteriorated. Revenue growth remains modest and uneven, and margins, while improved, are moderate for a branded pharma company. The strong balance sheet (score 78) partially offsets weaker cash flow trends (score 58) and moderate income statement performance (score 62).

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Income Statement
Total Revenue	293.97B	300.00B	309.21B	301.96B	279.04B	266.26B
Gross Profit	165.58B	171.03B	170.68B	178.71B	166.09B	156.59B
EBITDA	61.44B	68.14B	67.41B	50.72B	12.95B	52.93B
Net Income	31.50B	36.26B	39.62B	26.64B	-14.95B	27.22B
Balance Sheet
Total Assets	408.12B	409.28B	424.87B	435.70B	421.18B	459.98B
Cash, Cash Equivalents and Short-Term Investments	84.58B	93.99B	83.35B	94.96B	58.68B	84.31B
Total Debt	243.69M	34.23B	34.90B	35.16B	36.21B	32.93B
Total Liabilities	127.91B	124.10B	127.57B	130.33B	127.88B	123.13B
Stockholders Equity	281.26B	286.24B	298.28B	306.06B	293.98B	337.49B
Cash Flow
Free Cash Flow	42.74B	54.27B	38.87B	61.96B	12.56B	10.20B
Operating Cash Flow	48.84B	60.93B	46.12B	72.65B	37.15B	46.04B
Investing Cash Flow	-7.22B	-8.22B	-13.76B	-6.14B	-26.78B	-35.17B
Financing Cash Flow	-34.48B	-53.31B	-52.32B	-34.03B	-37.22B	5.56B

Santen Pharmaceutical Co Technical Analysis

Technical Analysis SentimentPositive

Last Price11.23

Price Trends

50DMA11.12Positive

100DMA11.79Negative

200DMA11.44Negative

Market Momentum

MACD0.05Negative

RSI62.30Neutral

STOCH93.17Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Positive. The current price of 11.23 is above the 20-day moving average (MA) of 10.87, above the 50-day MA of 11.12, and below the 200-day MA of 11.44, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 62.30 is Neutral, neither overbought nor oversold. The STOCH value of 93.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNPHY.

Santen Pharmaceutical Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SNPHY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
ABBV	72Outperform	$521.11B	50.58	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$296.91B	31.19	24.24%	2.95%	1.64%	-28.72%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
SNPHY	58Neutral	$3.64B	15.03	13.39%	2.00%	-3.73%	26.50%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

SNPHY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SNPHY	Santen Pharmaceutical	11.36	1.43	14.44%
LLY	Eli Lilly And Company	1417.54	516.36	57.30%
MRK	Merck & Company	149.52	68.05	83.53%
NVS	Novartis AG	160.79	38.18	31.14%
PFE	Pfizer Inc	30.52	7.81	34.41%
ABBV	Abbvie	294.89	85.27	40.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 10, 2026

Santen Pharmaceutical Co AI Stock Analysis